Both hormones also regulate food intake, and the success of GLP1R agonists and dual GLP1R/GIPR agonists in the treatment of obesity has kindled ongoing research to better understand which target cells are most relevant for these pharmacological outcomes. Here, GIPR is linked to obesity disorder.